GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Return-on-Tangible-Asset

BioDelivery Sciences International (FRA:BD5) Return-on-Tangible-Asset : 115.48% (As of Dec. 2021)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioDelivery Sciences International's annualized Net Income for the quarter that ended in Dec. 2021 was €226.2 Mil. BioDelivery Sciences International's average total tangible assets for the quarter that ended in Dec. 2021 was €195.9 Mil. Therefore, BioDelivery Sciences International's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2021 was 115.48%.

The historical rank and industry rank for BioDelivery Sciences International's Return-on-Tangible-Asset or its related term are showing as below:

FRA:BD5' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -118.41   Med: -29.18   Max: 41.62
Current: 41.62

During the past 13 years, BioDelivery Sciences International's highest Return-on-Tangible-Asset was 41.62%. The lowest was -118.41%. And the median was -29.18%.

FRA:BD5's Return-on-Tangible-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.83 vs FRA:BD5: 41.62

BioDelivery Sciences International Return-on-Tangible-Asset Historical Data

The historical data trend for BioDelivery Sciences International's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Return-on-Tangible-Asset Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.02 -61.04 -16.34 16.32 39.37

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.69 11.40 18.70 13.94 115.48

Competitive Comparison of BioDelivery Sciences International's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Return-on-Tangible-Asset falls into.



BioDelivery Sciences International Return-on-Tangible-Asset Calculation

BioDelivery Sciences International's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=75.101/( (151.086+230.394)/ 2 )
=75.101/190.74
=39.37 %

BioDelivery Sciences International's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=226.172/( (161.319+230.394)/ 2 )
=226.172/195.8565
=115.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2021) net income data.


BioDelivery Sciences International  (FRA:BD5) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


BioDelivery Sciences International Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines